Profil bibliographique

Birgit Schoeberl

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

139Publications signalées

4807Citations signalées

2Affiliations récentes

Institutions déclarées

Novartis (Switzerland)Novartis (United States)

Domaines associés

Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchCancer, Hypoxia, and MetabolismGrowth Hormone and Insulin-like Growth FactorsGlycosylation and Glycoproteins Research

Publications récentes

Accès ouvert 2025 article

Physiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5 kg treated with artemether–lumefantrine to supplement the clinical data from the CALINA study

Helen Gu, Nada Abla, Vinay Kumar Venishetty, Birgit Schoeberl et autres

2 citationsTropical Medicine and Health

2025 article

The Adoption and Use of Artificial Intelligence and Machine Learning in Clinical Development

Mary Jo Lamberti, Maria Florez, Hanh Do, Timothé Ménard et autres

1 citationTherapeutic Innovation & Regulatory Science

Accès ouvert 2024 article

Viral Kinetics Model of SARS‐CoV‐2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection

Allison Claas, Meelim J. Lee, Pai‐Hsi Huang, Charles G. Knutson et autres

6 citationsClinical Pharmacology & Therapeutics

2024 book-chapter

Future Directions for Quantitative Systems Pharmacology

Birgit Schoeberl, Cynthia J. Musante, Saroja Ramanujan

4 citationsHandbook of experimental pharmacology

Accès ouvert 2023 supplementary-materials

Supplementary Figures 1-4, Table 1 from Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Charlotte F. McDonagh, Alexandra Huhalov, Brian D. Harms, Sharlene Adams et autres

0 citations

Accès ouvert 2023 other

Data from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams et autres

0 citations

Accès ouvert 2023 supplementary-materials

Supplementary Figure Legends from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams et autres

0 citations

Accès ouvert 2023 supplementary-materials

Supplementary Table 4 from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams et autres

0 citations

Accès ouvert 2023 supplementary-materials

Supplementary Figures 1 through 10 and Supplementary Tables 1 through 3 from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams et autres

0 citations

Accès ouvert 2023 supplementary-materials

Supplementary Materials and Methods from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams et autres

0 citations

Accès ouvert 2023 supplementary-materials

Supplementary Figure Legend from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies

Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou et autres

0 citations

Accès ouvert 2023 supplementary-materials

Supplementary Table 3 from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies

Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.